Literature DB >> 33442956

Coexistence of atypical adenomatous hyperplasia, minimally invasive adenocarcinoma and invasive adenocarcinoma: Gene mutation analysis.

Junya Song1, Yinghui Xu1, Zhiguang Yang2, Yunpeng Liu2, Peng Zhang2, Xu Wang1, Chao Sun1, Ye Guo1, Shi Qiu1, Guoguang Shao2, Kewei Ma1.   

Abstract

Multiple primary lung cancer (MPLC) refers to the simultaneous occurrence of two or more lung primary malignant tumors in one individual. The detection rate of MPLC has increased significantly in recent years, and the distinction between MPLC and lung metastasis has strong clinical significance. Whole exome sequencing (WES) can clearly identify the heterogeneity between MPLC nodules. Here, we report a case of a 50-year-old Asian female without a history of smoking. She underwent a lung computed tomography (CT) scan and three ground-glass nodules (GGNs) were found which were pathologically confirmed as atypical adenomatous hyperplasia (AAH), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IA), respectively. We performed WES on the three pulmonary nodules and analyzed the sequencing results. We believe that this is the first published report of a case of "three phases" of lung adenocarcinoma analyzed by WES. Under the same genetic background and internal environment, these three nodules showed significant genetic differences and developed into "three phases" of lung adenocarcinoma. Analysis of the WES results supported the lung adenocarcinoma model from AAH to MIA and IA, and explored possible potential driver genes and therapeutic targets. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: We used WES to analyze the gene mutation status of three tumors in one individual. We found that even if under the same genetic background, AAH, MIA and IA showed significant genetic differences and developed into "three phases" of lung adenocarcinoma. WHAT THIS STUDY ADDS: Analysis of the WES results supported the lung adenocarcinoma model from AAH to MIA and IA, and explored possible potential driver genes and therapeutic targets.
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Multiple primary lung cancer (MPLC); mutation spectrum; phylogenetic tree; tumor mutation burden (TMB); whole exome sequencing (WES)

Year:  2021        PMID: 33442956      PMCID: PMC7919134          DOI: 10.1111/1759-7714.13798

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  18 in total

1.  New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile.

Authors:  Myriam Ruault; Pierre van der Bruggen; Marie-Elisabeth Brun; Shelagh Boyle; Gérard Roizès; Albertina De Sario
Journal:  Eur J Hum Genet       Date:  2002-12       Impact factor: 4.246

Review 2.  Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway.

Authors:  Richard J Orton; Oliver E Sturm; Vladislav Vyshemirsky; Muffy Calder; David R Gilbert; Walter Kolch
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

3.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 4.  Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Authors:  Michael Allgäuer; Jan Budczies; Petros Christopoulos; Volker Endris; Amelie Lier; Eugen Rempel; Anna-Lena Volckmar; Martina Kirchner; Moritz von Winterfeld; Jonas Leichsenring; Olaf Neumann; Stefan Fröhling; Roland Penzel; Michael Thomas; Peter Schirmacher; Albrecht Stenzinger
Journal:  Transl Lung Cancer Res       Date:  2018-12

5.  A scored human protein-protein interaction network to catalyze genomic interpretation.

Authors:  Taibo Li; Rasmus Wernersson; Rasmus B Hansen; Heiko Horn; Johnathan Mercer; Greg Slodkowicz; Christopher T Workman; Olga Rigina; Kristoffer Rapacki; Hans H Stærfeldt; Søren Brunak; Thomas S Jensen; Kasper Lage
Journal:  Nat Methods       Date:  2016-11-28       Impact factor: 28.547

Review 6.  Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma.

Authors:  Wilko Weichert; Arne Warth
Journal:  Curr Opin Pulm Med       Date:  2014-07       Impact factor: 3.155

7.  Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway.

Authors:  Lian Yi; Tujin Shi; Marina A Gritsenko; Chi-Yuet X'avia Chan; Thomas L Fillmore; Becky M Hess; Adam C Swensen; Tao Liu; Richard D Smith; H Steven Wiley; Wei-Jun Qian
Journal:  Anal Chem       Date:  2018-04-03       Impact factor: 6.986

8.  Genomic heterogeneity of multiple synchronous lung cancer.

Authors:  Yu Liu; Jianjun Zhang; Lin Li; Guangliang Yin; Jianhua Zhang; Shan Zheng; Hannah Cheung; Ning Wu; Ning Lu; Xizeng Mao; Longhai Yang; Jiexin Zhang; Li Zhang; Sahil Seth; Huang Chen; Xingzhi Song; Kan Liu; Yongqiang Xie; Lina Zhou; Chuanduo Zhao; Naijun Han; Wenting Chen; Susu Zhang; Longyun Chen; Wenjun Cai; Lin Li; Miaozhong Shen; Ningzhi Xu; Shujun Cheng; Huanming Yang; J Jack Lee; Arlene Correa; Junya Fujimoto; Carmen Behrens; Chi-Wan Chow; William N William; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; Jun Wang; Dongmei Lin; Xiangyang Liu; P Andrew Futreal; Yanning Gao
Journal:  Nat Commun       Date:  2016-10-21       Impact factor: 14.919

9.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

10.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.